The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 28, 2026

Filed:

Oct. 29, 2021
Applicant:

Chemocentryx, Inc., San Carlos, CA (US);

Inventors:

XI Chen, E. Palo Alto, CA (US);

Junfa Fan, Foster City, CA (US);

Pingchen Fan, Fremont, CA (US);

Antoni Krasinski, San Jose, CA (US);

Lianfa Li, San Jose, CA (US);

Rebecca M. Lui, Santa Clara, CA (US);

Jeffrey P. Mcmahon, San Francisco, CA (US);

Jay P. Powers, Pacifica, CA (US);

Yibin Zeng, Foster City, CA (US);

Penglie Zhang, Foster City, CA (US);

Assignee:

CHEMOCENTRYX, INC., Thousand Oaks, CA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/4709 (2006.01); A61K 31/415 (2006.01); A61K 31/4725 (2006.01); A61K 31/502 (2006.01); A61K 31/517 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01); A61P 1/04 (2006.01); A61P 11/06 (2006.01); A61P 19/02 (2006.01); A61P 31/18 (2006.01); C07D 231/42 (2006.01); C07D 401/04 (2006.01); C07D 401/06 (2006.01); C07D 401/10 (2006.01); C07D 403/04 (2006.01); C07D 403/10 (2006.01); C07D 405/14 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4709 (2013.01); A61K 31/415 (2013.01); A61K 31/4725 (2013.01); A61K 31/502 (2013.01); A61K 31/517 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); A61P 1/04 (2018.01); A61P 11/06 (2018.01); A61P 19/02 (2018.01); A61P 31/18 (2018.01); C07D 231/42 (2013.01); C07D 401/04 (2013.01); C07D 401/06 (2013.01); C07D 401/10 (2013.01); C07D 403/04 (2013.01); C07D 403/10 (2013.01); C07D 405/14 (2013.01);
Abstract

Compounds are provided that act as potent antagonists of the CCR(9) receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR(9). The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR(9)-mediated diseases, and as controls in assays for the identification of CCR(9) antagonists.


Find Patent Forward Citations

Loading…